17 results about "Amifostine" patented technology

The invention discloses application of amifostine to improvement of fixed-point insertion efficiency of a genome, and belongs to the field of biological medicine. Specifically, amifostine provided by the invention can significantly improve the CRISPR gene editing efficiency, and especially can be used for preparing non-viral site-specific integrated CAR T cells. Through cell experiments, it is found that amifostine has a remarkable promoting effect on the positive rate of CAR T cells after electrotransfection, and the tumor killing function of the T cells is greatly improved.

The application discloses application of amifostine in improving genome site-directed insertion efficiency and belongs to the field of biological medicines. Specifically, the application proposes that amifostine can significantly increase the efficiency of CRISPR gene editing, and can be used for preparing non-viral site-directed integration CAR T cells. It is found through cell experiments that amifostine has a significant promoting effect on the positive rate of CAR T cells after electrotransformation, and greatly improves the tumor killing function of T cells.

The invention belongs to the technical field of biological medicine, and provides an iron-based nanodot capable of guiding MRI and delivering medicine and a preparation method and application of the iron-based nanodot. The iron-based nanodot is used as a chemotherapeutic drug carrier, and is prepared from a cell protective agent amifostine (AT) and key nutritional metal iron ions (Fe < 3 + >) for inducing ferroptosis through a supramolecular self-assembly technology. The iron-based nanodot can efficiently load the chemotherapeutic drug, improves pharmacokinetic behaviors such as short in-vivo circulation period and fast metabolism of the chemotherapeutic drug, accurately delivers the chemotherapeutic drug to a tumor site, and improves the drug effect of the chemotherapeutic drug; in addition, the iron-based nanodots can realize efficient ferroptosis treatment under the guidance of MRI to induce immunogenic cell death and inhibit growth, metastasis and diffusion of tumor cells.

The application provides a kind of gamma delta T cell preparation and its preparation method and application, it is related to the field of biotechnology.The composition provided by the application includes: coenzyme Q10, vitamin C, human blood albumin, trehalose, sodium pyruvate and amifostine.Using the composition and related preparation provided by the application can effectively improve the killing ability of gamma delta T cells and maintain the function of gamma delta T cells, and can effectively inhibit tumor growth.

The present invention provides a composition comprising 5-aminolevulinic acid or a salt or ester thereof, comprising: (a) an active ingredient selected from 5-aminolevulinic acid or a salt or ester thereof; and (b) an aqueous carrier comprising an analgesic. The 5-aminolevulinic acid or the salt or ester thereof can be used for photodynamic therapy analgesia for more than 20 minutes, so that the clinical treatment cycle can be covered, the pain feeling after photodynamic therapy can be obviously relieved, the photodynamic therapy receiving time of a patient is prolonged, and the medication compliance of the patient is improved. Moreover, the composition provided by the invention can also improve the condition of tissue edema after photodynamic therapy, improve the skin smoothness after photodynamic therapy and shorten the pigmentation time, and meanwhile, compared with a marketed preparation, the composition has a better effect in the aspect of photodynamic therapy of inflammatory diseases (such as psoriasis or contact dermatitis) or acne and the like, and has a good application prospect. The acceptability of the patient to the photodynamic therapy is further improved; and the application scene of the photodynamic therapy is widened.

According to the invention, a nano molecular system (ACu-NPs) based on amifostine and copper ions is innovatively constructed. According to the system, Cu < 2 + > is specifically released through a tumor microenvironment, the problem of non-specific distribution of copper ions in vivo is effectively solved, and toxicity to normal cells is avoided. Through a Fenton-like reaction catalyzed by Cu (II) / Cu (I), the system can consume glutathione (GSH) in tumor cells, promote generation of reactive oxygen species (ROS), remarkably reverse a tumor immunosuppression microenvironment and overcome the problem of low response rate of an immune checkpoint blocking (ICB) therapy. Besides, ACu-NPs generates WR-1065 through metabolism of alkaline phosphatase (ALP) in normal cells, ROS is removed, the normal cells are protected against oxidative damage, and the problem of toxicity of a traditional copper ion carrier to normal tissues is effectively solved. The invention provides an innovative dual treatment strategy for treating primary and metastatic tumors.

A colon-targeted delivery system, a preparation method and application thereof, comprising amifostine, pectin and chitosan; through a chemical amidation reaction, carboxyl in the pectin and amino in the amifostine are connected through an amide bond to form a nanoparticle core PEC-AMF, and the chitosan and the pectin form a nanoparticle coating layer through electrostatic interaction to synthesize CS / PEC-AMF nanoparticles; the colon-targeted delivery system in the application realizes precise and controlled drug release by means of the step-by-step change of pH values in the gastrointestinal tract environment and the catalysis of pectinase in the colon; experiments prove that the delivery system has excellent stability in the stomach and small intestine, and can rapidly release amifostine in the colon, thereby effectively protecting the intestinal epithelium and immune cells from damage caused by radiotherapy, while the pectin regulates the intestinal microecology, protects the normal tissues of the colorectum and does not affect the effect of radiotherapy on tumors.

The invention discloses a preparation method of an oral radiation protection nano-drug, which comprises the following steps: grafting amifostine onto carboxymethyl chitosan under the condition of normal temperature through a 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide (EDC) and N-hydroxysuccinimide (EDC / NHS) catalytic system in 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride; the pH response type radiation protection nano-drug is synthesized by a one-step method. Intestinal radiation protection can be achieved by orally taking the pH response type radiation protection nano-drug, the nano-drug has pH sensitivity and can achieve targeted intestinal radiation protection, the bioavailability of the small molecule drug amifostine in the gastrointestinal tract can be effectively improved, the biotoxicity of the small molecule drug amifostine can be effectively reduced, and the nano-drug has important significance in the field of intestinal radiation protection.

The invention provides a gamma delta T cell preparation as well as a preparation method and application thereof, and relates to the technical field of biology. The composition provided by the invention comprises coenzyme Q10, vitamin C, human serum albumin, trehalose, sodium pyruvate and amifostine. By using the composition and the related preparation provided by the invention, the killing ability of gamma delta T cells can be effectively improved, the functions of the gamma delta T cells can be maintained, and tumor growth can be effectively inhibited.

The present invention belongs to the field of pharmaceutical analysis and detection, and relates to a method for detecting the purity of amifostine intermediate M2 and its related substances. The chromatographic conditions are a chromatographic column filled with unbonded silica gel particles; acetonitrile is used as mobile phase A, and a 50 mmol / L ammonium formate solution adjusted to pH 2.2 with formic acid is used as mobile phase B, and mobile phases A and B are mixed in a certain proportion for gradient elution. The detection method provided by the present invention can quickly and accurately detect the purity of amifostine intermediate M2 and the content of its related substances. In particular, the content of the genotoxic impurity M2-A can be monitored in intermediate M2, thereby indicating that there may be a safety risk in intermediate M2 compound, and it is necessary to effectively control the content of genotoxic impurity M2-A in the intermediate process; thus, it can ensure that the content of genotoxic impurity M2-A flowing into the amifostine API in the subsequent reaction meets the quality standards, which is of great significance for the synthesis and quality control of the final product amifostine.

The invention belongs to the technical field of medicines, and discloses application of orlistat in preparation of a medicine for preventing and treating cisplatin-induced renal injury. The invention discloses application of orlistat or pharmaceutically acceptable salts thereof in prevention and / or treatment of renal injury for the first time. In-vitro cell experiments show that orlistat obviously inhibits toxicity of cis-platinum on renal tubular epithelial cells, DNA damage is inhibited, ROS generation is reduced, endoplasmic reticulum stress is improved, and cell apoptosis is inhibited. Animal experiments show that orlistat can significantly improve the toxicity of cis-platinum to mice, increase the survival rate of the mice, recover the weight of the mice, improve pathological injury of kidneys, inhibit secretion of inflammatory factors, reduce creatinine and urea nitrogen and reverse electrolyte disorder. Particularly, orlistat does not affect the anti-tumor efficacy of cis-platinum at the cellular level and in a tumor-bearing mouse body, and the protection effect of orlistat on kidney injury induced by cis-platinum is superior to that of the unique clinical drug amifostine.

The invention discloses a kind of nanoparticles of load amifostine and its preparation method and application, belong to the field of pharmaceutical technology; The nanoparticles of load amifostine of the present invention are spherical shell-core structure, including PLGA core and DSPE PEG AMF and PS 80 surrounding the outside of PLGA core, and the particle diameter of the nanoparticles is 50 500nm. The nanoparticles of load amifostine provided by the present invention can enter the brain through the blood-brain barrier after ophthalmic vein injection, are converted into active form after metabolism by alkaline phosphatase on the surface of normal brain cells, play the role of scavenging oxygen free radicals (ROS), so as to prevent the occurrence of radiation brain injury, the nanoparticles of load amifostine obtained are significantly better than original drug amifostine in the preventive effect on brain injury, can be applied to the preparation of medicines for preventing radiation brain injury (RIBI); and the preparation method provided by the present invention is simple, which is conducive to actual production.

The application discloses a preparation method of an oral radiation protection nano drug, and the preparation method is characterized in that 1-(3-dimethylaminopropyl)-3-ethyl carbodiimide hydrochloride (EDC) and N-hydroxysuccinimide (EDC / NHS) catalytic systems are used to graft amifostine to carboxymethyl chitosan under normal temperature conditions, and a pH-responsive radiation protection nano drug is synthesized by one-step method. The oral pH-responsive radiation protection nano drug can realize intestinal radiation protection, the nano drug has pH sensitivity and can realize targeted intestinal radiation protection, can effectively improve the bioavailability of a small-molecule drug amifostine in a gastrointestinal tract and reduce the biological toxicity of the small-molecule drug, and has important significance in the field of intestinal radiation protection.

The present invention relates to a process for the preparation of lyophilized 2-[(3-aminopropyl)amino]ethanethiol comprising the following steps: a) reacting an amifostine solution with a strong acid to obtain a 2-[(3-aminopropyl)amino]ethanethiol solution, and b) lyophilizing the 2-[(3-aminopropyl)amino]ethanethiol solution, with or without the addition of excipients.

The invention discloses a colon targeted delivery system as well as a preparation method and application thereof. The colon targeted delivery system comprises amifostine, pectin and chitosan, the preparation method comprises the following steps: carrying out chemical amidation reaction on pectin and amifostine, connecting carboxyl in the pectin with amino in the amifostine through an amido bond to form a nanoparticle core PEC-AMF, and carrying out electrostatic interaction on chitosan and the pectin to form a nanoparticle wrapping layer to synthesize CS / PEC-AMF nanoparticles; according to the colon targeted delivery system, after oral administration, accurate and controlled drug release is realized by virtue of a pH value which changes step by step in a gastrointestinal tract environment and a specific pectinase catalysis effect in colon; experiments prove that the delivery system has excellent stability in the stomach and the small intestine, and can quickly release amifostine at the colon part, so that the intestinal epithelium and immune cells are effectively protected from damage caused by radiotherapy, and meanwhile, pectin regulates the intestinal microecology and protects normal tissues of colorectum without influencing the effect of radiotherapy on tumors.

The invention provides application of combination of amifostine and calycosin in preparation of a preparation for preventing and / or treating radiation-induced lung injury, and belongs to the technical field of medicines. According to the invention, the amifostine and the calycosin are combined for use, so that the medication side effect caused by independent use of the amifostine in the prior art is effectively solved, and the prevention effect and the treatment stability of the amifostine are improved. According to the pharmaceutical composition disclosed by the invention, the amifostine and the calycosin are combined for use, so that the pharmaceutical composition has a good prevention and treatment effect on radiation-induced lung injury caused by ionizing radiation, and adverse reactions such as hypotension and nausea generated when the amifostine is independently used cannot be generated. And when the administration dosage of the amifostine and the calycosin is low, the survival rate of a radiation-induced lung injury model mouse is remarkably improved, and no toxic or side effect exists.